RxDoctor Payments Data

Robert Kirsner, MD

Dermatology · Miami, FLNPI 1518991314

Payments from drug & device makers

What this record shows

This record is dominated by other: $1,087,825 of the $1,416,682 with a category attached, or 76.8%. Kerecis Limited accounts for 78.8% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2023 at $1,124,876 and has fallen 94.6% since, to $60,783 in 2025. Among dermatology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,416,682in general payments, 2019–2025

Across 276 payments — averaging $5132.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kerecis Limited$1.1M
  • Molnlycke Health Care US, LLC$116K
  • Smith+Nephew$80K
  • Pfizer$29K
  • Organogenesis Inc.$16K
  • Urgo Medical North America, LLC$15K
  • plus $45K from 25 others
$156,773in research payments, 2019–2025

Across 61 payments — averaging $2570.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Smith+Nephew$124K
  • Regeneron$12K
  • Boehringer Ingelheim International GmbH$10K
  • Pfizer$6K
  • Biotissue Holdings Inc.$4K
  • Medline Industries LP$1K
  • plus $87 from 1 others

What the payments were for

  • Consulting fees$255,72318%
  • Speaking & faculty fees$29,0072%
  • Grants$2,5000%
  • Travel & lodging$33,8972%
  • Food & beverage$7,7161%
  • Education$140%
  • Other$1,087,82577%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,416,682 in reported general payments places this provider in the 95th percentile of 1,147 dermatology providers in Florida.

See all dermatology providers in Florida

Medicare billing

Part B allowed, 2024
$155,127
Medicare patients
405
Services billed
2,266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa20$434,797
Dupixent SyringeDupilumab38$142,779
Dupixent PenDupilumab21$85,269
Enbrel SureclickEtanercept11$70,749
Bexarotene12$35,712
Cyclosporine12$12,752
Acitretin45$5,605
Tacrolimus23$4,636
Cyclosporine ModifiedCyclosporine, Modified28$3,845
Clobetasol Propionate69$3,093
Pregabalin65$1,816
Triamcinolone Acetonide118$1,741
Pentoxifylline31$1,475
Metronidazole25$1,286
Ketoconazole97$1,254

Paid to pharmacies, not to this prescriber.

Other dermatology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →